GSK said on Friday that it has sold its remaining 4.2% stake in consumer health business Haleon, which it spun off in July 2022.
Source: Sharecast
The pharmaceutical company sold just over 385m ordinary shares in Haleon at 324p each, raising gross proceeds of about £1.25bn.
GSK initially retained a 12.9% stake in Haleon, but had since sold stakes in May 2023, October 2023 and January 2024.
"GSK's exit of its position in Haleon is consistent with its previous commitments to monetise its holding in a disciplined manner," it said.
If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.